Skip to Main Content
Table 4

Correlation of ETAR expression with DFST according to clinicopathological variablesa

Clinicopathological variablesETAR statusDFSTP                  b
Months (95% CI)
Tumor size    
 ≤2 cm Negative 97 (87–106) NSc; 0.141 
 Positive 82 (66–98)  
Tumor size    
 >2 cm Negative 82 (69–96) NS; 0.194 
 Positive 67 (51–83)  
Lymph node negative Negative 95 (85–104) NS; 0.424 
 Positive 86 (72–101)  
Lymph node positive Negative 80 (64–95) NS; 0.145 
 Positive 61 (45–76)  
Invasive ductal Negative 88 (77–100) NS; 0.296 
 Positive 74 (60–87)  
Invasive lobular Negative 73 (54–92) NS; 0.331 
 Positive 90 (64–115)  
Special Negative 105 (94–116) 0.003 
 Positive 62 (40–84)  
Histologic grade I–II Negative 96 (87–93) 0.046 
 Positive 78 (64–93)  
Histologic grade III Negative 71 (52–91) NS; 0.837 
 Positive 67 (49–86)  
ER positive Negative 96 (85–106) 0.011 
 Positive 71 (58–85)  
ER negative Negative 76 (63–89) NS; 0.922 
 Positive 75 (54–96)  
PR positive Negative 95 (84–106) NS; 0.090 
 Positive 79 (64–95)  
PR negative Negative 76 (64–88) NS; 0.327 
 Positive 66 (50–83)  
Her-2/neu negative Negative 88 (80–97) 0.035 
 Positive 71 (58–83)  
Her-2/neu positive Negative 79 (56–102) NS; 0.627 
 Positive Censored  
MIB-1 labeling index ≤20% Negative 92 (82–102) 0.002 
 Positive 64 (50–78)  
MIB-1 labeling index >20% Negative 82 (65–99) NS; 0.503 
 Positive 86 (68–104)  
Lymphovascular invasion absent Negative 93 (84–101) 0.033 
 Positive 75 (62–88)  
Lymphovascular invasion present Negative 65 (41–88) NS; 0.965 
 Positive 66 (44–88)  
No inflammatory component Negative 90 (81–99) NS; 0.059 
 Positive 75 (63–86)  
Inflammatory component Negative 77 (40–115) 0.045 
 Positive  
Clinicopathological variablesETAR statusDFSTP                  b
Months (95% CI)
Tumor size    
 ≤2 cm Negative 97 (87–106) NSc; 0.141 
 Positive 82 (66–98)  
Tumor size    
 >2 cm Negative 82 (69–96) NS; 0.194 
 Positive 67 (51–83)  
Lymph node negative Negative 95 (85–104) NS; 0.424 
 Positive 86 (72–101)  
Lymph node positive Negative 80 (64–95) NS; 0.145 
 Positive 61 (45–76)  
Invasive ductal Negative 88 (77–100) NS; 0.296 
 Positive 74 (60–87)  
Invasive lobular Negative 73 (54–92) NS; 0.331 
 Positive 90 (64–115)  
Special Negative 105 (94–116) 0.003 
 Positive 62 (40–84)  
Histologic grade I–II Negative 96 (87–93) 0.046 
 Positive 78 (64–93)  
Histologic grade III Negative 71 (52–91) NS; 0.837 
 Positive 67 (49–86)  
ER positive Negative 96 (85–106) 0.011 
 Positive 71 (58–85)  
ER negative Negative 76 (63–89) NS; 0.922 
 Positive 75 (54–96)  
PR positive Negative 95 (84–106) NS; 0.090 
 Positive 79 (64–95)  
PR negative Negative 76 (64–88) NS; 0.327 
 Positive 66 (50–83)  
Her-2/neu negative Negative 88 (80–97) 0.035 
 Positive 71 (58–83)  
Her-2/neu positive Negative 79 (56–102) NS; 0.627 
 Positive Censored  
MIB-1 labeling index ≤20% Negative 92 (82–102) 0.002 
 Positive 64 (50–78)  
MIB-1 labeling index >20% Negative 82 (65–99) NS; 0.503 
 Positive 86 (68–104)  
Lymphovascular invasion absent Negative 93 (84–101) 0.033 
 Positive 75 (62–88)  
Lymphovascular invasion present Negative 65 (41–88) NS; 0.965 
 Positive 66 (44–88)  
No inflammatory component Negative 90 (81–99) NS; 0.059 
 Positive 75 (63–86)  
Inflammatory component Negative 77 (40–115) 0.045 
 Positive  
a

Primary breast cancers only.

b

χ2 test.

c

NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal